JUL 04, 2020 5:53 PM PDT

New mechanism that supports the progression and relapse cancer discovered

Researchers have found a mechanism of a key protein that supports the progression and relapse of cancer. This discovery provides hope for improved treatment options that focus on targeting stem-like cells that are more susceptible to chemotherapy and immunotherapy. Their findings are published in the journal PNAS

"We discovered a mechanism involving MBNL1 protein that predicts several characteristics of cancer such as progression and relapse," said lead author Dr. Debleena Ray, Senior Research Fellow at Duke-NUS' Cancer and Stem Cell Biology (CSCB) program. "We found that MBNL1 protein is present in low amounts in many of the common cancers in the world, including breast, colorectal, stomach, lung and prostate cancers, which when combined account for about 49% of all cancers diagnosed in 2018. This can cause poor overall survival in many of these commonly-occurring cancers."

Source: Pixabay

Cancer is the second-highest leading cause of death globally and cancer cases are on the rise. Professor Patrick Casey, Senior Vice Dean for Research at Duke-NUS, explains why this finding is so critical: 

"Cancer is a global health challenge and Singapore is no exception. This study provides important information about novel targets and biomarkers that are implicated in several major cancers, which could lead to the development of new treatment strategies that can improve the lives of patients."

In addition to the discovery of this mechanism, the team also identified that reversing the mechanism resulted in the inhibition of the JNK protein in cancer cells with low levels of MBNL1. JNK is known to be an established target in certain cancer treatments. 

"While JNK inhibitors have been tested as a cancer drug previously, currently there are no clinical trials for the same. However, if in the future there is a JNK inhibitor against cancer, MBNL1 could be used as a biomarker to select patients for the treatment," said co-corresponding author David Epstein at the Duke-NUS' CSCB program.

The researchers plan to continue their investigations of MBNL1 and JNK involving antisense technology, a tool that is used for the inhibition of gene expression.

Sources: PNAS, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
OCT 05, 2020
Health & Medicine
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
OCT 05, 2020
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
Even with the best anti-nausea medications one in three patients receiving chemotherapy experiences vomiting, and about ...
OCT 07, 2020
Cancer
Beyond the eye: improving melanoma detection
OCT 07, 2020
Beyond the eye: improving melanoma detection
Research from UC San Francisco reports that it is possible to use genomic methods to detect skin damage from the sun not ...
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
NOV 24, 2020
Clinical & Molecular DX
Young Inventor Creates Award-winning At-home Cancer Diagnostic
NOV 24, 2020
Young Inventor Creates Award-winning At-home Cancer Diagnostic
Getting a breast cancer diagnosis often means having to endure multiple tests, including some painful and invasive proce ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
DEC 01, 2020
Cancer
The price tag of prostate cancer treatment
DEC 01, 2020
The price tag of prostate cancer treatment
New research published in The Journal of Urology from the Official Journal of the American Urological Association&n ...
Loading Comments...